retatrutide clinical trial results retatrutide Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide NEW Phase 3 Clinical

Think about what that means

The cost of retatrutide through research suppliers currently runs higher per milligram than compounded tirzepatide, largely because of limited manufacturing scale and the absence of compounding pharmacy competition

Researchers are interested in its unique mechanism and the possibility that combining three metabolic pathways may produce different outcomes compared with single-pathway approaches

Limitations In our systematic review, we did not prioritize the risk of bias evaluation

By combining compliance-driven manufacturing, patient-centered design, and flexible customization, NEST helps pharmaceutical partners bring safer and more convenient injectable therapies to market.

A 2025 meta-analysis found tirzepatide (the drug in Mounjaro and Zepbound) lowered inflammation markers hsCRP by about 33% and IL-6 by about 18% versus placebo